The discovery that common herpes viruses manipulate a specific cellular enzyme to trigger cancer represents a significant advance in understanding virus-driven malignancies. This finding could reshape prevention and treatment strategies for millions of people carrying these widespread pathogens.
Researchers identified NEK2 kinase as the critical molecular target that Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) exploit to destabilize chromosomes and drive uncontrolled cell division. The viral latency proteins EBNA2 and LANA directly upregulate NEK2 expression through the RBP-Jκ signaling pathway, creating the genomic chaos necessary for tumor formation. This represents the first demonstration of how these viruses coordinate chromosomal instability through a single host enzyme.
The implications extend far beyond basic virology. EBV infects over 90% of adults worldwide and contributes to lymphomas, nasopharyngeal carcinoma, and gastric cancers. KSHV causes Kaposi's sarcoma and several lymphoproliferative disorders. Together, these viruses account for approximately 200,000 cancer cases annually. Understanding their shared mechanism through NEK2 opens therapeutic possibilities that current antiviral approaches cannot address.
The research reveals how these viruses remain dormant for decades while subtly reprogramming cellular machinery. Rather than immediate destruction, they establish persistent infections that gradually accumulate DNA damage through NEK2 overactivation. This patience strategy explains why virus-associated cancers often emerge years after initial infection. The findings suggest NEK2 inhibitors, already under development for other cancers, might prevent or treat herpes virus-driven malignancies—a potentially transformative application for existing drug development pipelines.